| A45 | Higher comorbidity and comedication burden in women and young people living with HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A45 | Overt expression of IL-32 isoforms in the colon of ART-treated PLWH: negative regulation by IL-17A | E-poster | Co-morbidities: Non-communicable diseases |
| A45 | Baricitinib reduces macrophage-mediated inflammation in HIV infection | E-poster | Co-morbidities: Non-communicable diseases |
| A45 | BMI as a predictor of high fasting blood glucose among people living with HIV in the Asia-Pacific region | E-poster | Co-morbidities: Non-communicable diseases |
| A46 | Correlation between serum and salivary HIV antibodies in a cohort of well-controlled children living with perinatal HIV/AIDS | E-poster | Novel assays to measure immune responses |
| A49 | Antibody responses of cows immunized with HIV V2-apex focusing immunogens | E-poster | Novel animal models to test interventions (vaccines, cure, antiretrovirals) |
| A5 | Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' between innate and adaptive immune cells in HIV controllers on ART | On-demand oral abstract session | Innate immunity |
| A5 | Extracellular vehicles carrying HIV-1 Nef induce trained immunity in myeloid cells | E-poster | Innate immunity |
| A5 | Robust anti-viral immune responses at the placenta during early gestation limit in utero HIV infection and replication | E-poster | Innate immunity |
| A6 | Plasma IL-21 associates with HIV-1 Neutralising potency of polyclonal IgG in the periphery | On-demand oral abstract session | Humoral immunity (including broadly neutralizing antibodies) |